STE

STERIS stock has delivered a positive 11.2% total return over the past five years, yet current checks suggest the shares now trade close to a fair level rather than offering an obvious discount. The intrinsic value estimate from a Discounted Cash Flow (DCF) framework is slightly below the recent market price, and the broader valuation tools also lean toward STERIS being on the expensive side. Over five years, STERIS has returned 11.2%, which points to modest long term gains rather than a runaway winner. Future cash flow growth from its infection prevention and sterilization businesses can support the current price. However, any pressure on hospital capital spending or procedure volumes may limit how much investors are willing to pay for that cash flow. The broader valuation checks suggest STERIS is not a clear bargain, with the company scoring 0 out of 6 on this valuation screen. The issue now is whether STERIS offers enough long term cash flow potential at today’s valuation to justify taking on the recent share price softness. Scan 54 high quality undervalued stocks to compare STERIS with other companies that pair solid cash generation with valuations that still leave more room for upside. The Discounted Cash Flow (DCF) model for STERIS is built on its cash generation rather than reported earnings. The latest twelve month free cash flow sits at about $886.9 million, and the projections assume a gradually growing cash flow profile rather than sharp swings. On that basis, the 2 Stage Free Cash Flow to Equity model points to an intrinsic value of about $219.87 per share. With the current share price coming in a little above that DCF estimate, the model implies STERIS is around 4.8% overvalued rather than clearly cheap. That premium is not extreme, and it suggests the market is already pricing in a steady stream of cash flows from the infection prevention and sterilization business, with limited margin for disappointment on growth or capital spending trends. On this DCF view, STERIS stock appears roughly fairly valued, with only a slight tilt toward being overvalued at today’s price. STERIS is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act. Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for STERIS. The P/E multiple is a useful cross check for STERIS because earnings remain a key lens for how investors value established medical equipment companies. STERIS currently trades on a P/E of about 27.9x, which is slightly above the peer average of 23.8x and also a touch higher than the wider medical equipment industry average of about 27.0x. The tailored fair P/E ratio for STERIS, which reflects its specific growth profile, margins, scale and risk, is estimated at around 26.8x. That is close to the current P/E, so the stock carries only a modest premium to this benchmark. The market therefore appears to be pricing STERIS as a solid, higher quality earner within its group, without stretching the multiple to an extreme level. On the P/E test, STERIS appears to be priced roughly in line with what the model suggests is a fair earnings multiple. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives pick up where the STERIS valuation checks leave off. They spell out which paths for STERIS' growth, margins and earnings would justify a meaningfully higher or lower share price from here, and they sit on Simply Wall St's Community page. Rather than focusing on a single model output, each Narrative lays out the assumptions behind its fair value so you can compare those expectations with future results as they are reported. You can add your voice to the Simply Wall St community by sharing a Narrative on STERIS that sets out a clear, number driven view on where its growth, margins and execution go from here. Put your case on the record and track how it holds up as new results arrive. Do you think there's more to the story for STERIS? Head over to our Community to see what others are saying! STERIS now appears roughly fairly valued on both the Discounted Cash Flow (DCF) intrinsic value estimate and its P/E multiple, with only a slight lean toward being overvalued. The broader checks still indicate a low value score, so the stock does not screen as a clear bargain despite the support from cash flow and earnings models. From this point, the key consideration is whether STERIS can continue turning its infection prevention and sterilization footprint into steady cash generation without requiring investors to pay a higher multiple for that stability. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include STE. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Interested in STERIS plc? Here are five stocks we like better. STERIS delivered a strong fiscal 2027 first quarter, with reported revenue up 7%, constant-currency organic growth of 6% and adjusted EPS up 11% to $2.59. Gross and EBIT margins also expanded despite inflation and tariff costs. Healthcare led segment performance, driven by 10% services growth and 9% consumables growth, while endoscopy and ambulatory surgery activity remained robust. AST and Life Sciences posted organic growth of 5% and 8%, respectively, though both faced margin pressure. The company is investing $600 million in a North Carolina chemistry complex that is expected to consolidate operations and generate more than a 10% return on invested capital within three to five years. STERIS maintained its fiscal 2027 revenue and EPS outlook and raised its quarterly dividend by $0.06 to $0.69. STERIS (NYSE:STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from the prior-year quarter, while constant-currency organic revenue rose 6%, driven by volume growth and 190 basis points of pricing, Chief Financial Officer Karen Burton said. Adjusted diluted earnings per share increased 11% to $2.59, and adjusted net income totaled $253.4 million. → Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling Gross margin rose 70 basis points year over year to 46%, supported by pricing and productivity improvements that were partly offset by inflation. EBIT margin increased 100 basis points to 23.8% of revenue, aided by gross-margin gains, favorable currency and operating-cost discipline. The company recorded $14 million in gross tariff costs during the quarter, excluding refunds, compared with $12 million a year earlier. STERIS received $4 million in tariff refunds, resulting in a $2 million year-over-year benefit from net tariffs, Burton said. The refunds were recorded in corporate results rather than allocated to operating segments. → No Hangover: Revisiting Microsoft One Week After Earnings Healthcare segment constant-currency organic revenue grew 6% in the quarter. Services revenue increased 10%, while consumables revenue rose 9%, benefiting from higher customer consumption, share gains and procedure growth in endoscopy, President and CEO Dan Carestio said. Healthcare capital equipment revenue rose 1%, with growth affected by shipment timing. However, capital equipment orders increased 4%, and ending backlog rose to $444 million. Carestio said the company expects solid full-year growth in the capital equipment business, citing market traction and the effect of prior capital sales on demand for related consumables, chemistry products, sterility assurance and services. → MarketBeat Week in Review – 08/03 - 08/07 Healthcare EBIT margin expanded 60 basis points to 24.8%. Volume, pricing, productivity and favorable mix were partly offset by inflation, business investments and tariffs. During the question-and-answer session, Carestio said the company had not seen a slowdown in hospital procedure activity affecting its business, highlighting particularly strong growth in ambulatory surgery centers and endoscopy. He said STERIS has about one-third of its Healthcare franchise tied to endoscopy-related activity. Carestio attributed elevated endoscopy activity in part to a greater focus on earlier detection and screening for colon cancer. He said the company was encouraged by current growth but could not say whether the higher level would be sustained. Applied Sterilization Technologies, or AST, posted 5% constant-currency organic revenue growth, including 6% growth in services. Carestio said service volumes remained light as customers continued to reduce existing inventory, though the company expects growth to improve during the second half as comparisons become easier and destocking conditions normalize. AST EBIT margin declined 60 basis points to 48%. Additional pricing was more than offset by higher depreciation and slightly lower productivity. Management reaffirmed expectations for 7% to 8% organic growth in the segment for the full fiscal year. Life Sciences constant-currency organic revenue increased 8%. Capital equipment revenue rose 17%, consumables increased 8% and services grew 2%. Backlog was approximately flat year over year at $110 million. Life Sciences EBIT margin fell 140 basis points to 42.1%, as pricing and volume growth were more than offset by unfavorable productivity and inflation. Carestio said broader manufacturing localization, including activity outside the United States, could create opportunities for the segment as pharmaceutical customers expand or duplicate production footprints. STERIS announced plans to invest $600 million in a Formulated Chemistry Center of Excellence in North Carolina, its largest-ever investment in a single manufacturing site. The project will include two facilities totaling 600,000 square feet for manufacturing, research and development, and distribution. The facility will produce infection-prevention and contamination-control chemistries used by healthcare and pharmaceutical customers. Carestio said the company’s healthcare and life sciences formulated chemistry businesses together generate more than $700 million in revenue. The center is expected to begin operating in phases within two to three years, starting with distribution. Once complete, STERIS expects to move work from chemistry manufacturing and distribution sites in St. Louis, Missouri, and Plymouth, Minnesota, and close those facilities. The company expects pretax restructuring charges of roughly $55 million to $70 million related to the consolidation, including about $40 million to $50 million of cash expenditures and $15 million to $20 million of non-cash charges. Less than $10 million of the charges are expected to be recorded in fiscal 2027. Carestio said the facility initially is expected to be cost neutral but should generate greater leverage over time through combined volumes, automation and lower labor requirements. The company expects the project to generate a return on invested capital above 10% within three to five years of opening. Management maintained its fiscal 2027 outlook for reported revenue growth of 7% to 8% and constant-currency organic growth of 6% to 7%. The adjusted earnings-per-share outlook also remained unchanged at $11.10 to $11.30, representing projected growth of 9% to 11% from fiscal 2026. Capital expenditures are now expected to total approximately $450 million in fiscal 2027, including about $75 million tied to the North Carolina project. STERIS expects the project to add about $350 million in capital spending during fiscal 2028 and the remaining $175 million in fiscal 2029. Free cash flow is now expected to reach $800 million for fiscal 2027, with first-quarter performance helping offset the increased capital spending. First-quarter free cash flow was $279.6 million, down from $326.5 million a year earlier, primarily due to a lower working-capital contribution. The company ended the quarter with $1.9 billion in total debt and gross debt-to-EBITDA of about 1.1 times. It repurchased $100 million of shares during the quarter, leaving $900 million under its authorization, and raised its quarterly dividend by $0.06 to $0.69, marking its 21st consecutive year of dividend increases. STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures. Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "STERIS Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

STERIS plc STE reported first-quarter fiscal 2027 adjusted earnings of $2.59 per share, up 10.7% year over year. The bottom line beat the Zacks Consensus Estimate by 1.97%, supported by higher volume, pricing, productivity and a favorable business mix. On a GAAP basis, earnings per share (EPS) were $2.04 compared with $1.79 cents in the prior-year quarter. Revenues rose 7.3% to $1.49 billion but missed the consensus mark by 0.83%. Constant-currency organic revenues increased 6.2%, while total backlog advanced 7.7% year over year to $553.9 million. Following the earnings announcement, STE stock fell 2.4% in after-market trading yesterday. The decline was likely due to investor concerns over the company’s modest top-line miss. Healthcare revenues increased 7.6% to $1.05 billion. Service revenues grew 9.6%, consumables revenues advanced 9.2% and capital equipment revenues rose 1.4%. Constant-currency organic growth was 6.4%. Healthcare operating income increased 10.5% to $260.2 million. The improvement reflected higher volume, pricing, productivity and favorable mix, partly offset by inflation and increased tariff costs. The segment’s backlog rose 10% to $444 million. AST revenues rose 5.8% to $297.6 million, driven by 6% service growth despite a 13% decline in capital equipment revenues. Segment operating income increased 4.5% to $142.9 million, as improved pricing was partly offset by higher depreciation and labor costs. Life Sciences revenues climbed 8.6% to $146.7 million. Capital equipment revenues rose 17%, consumables increased 8% and service revenues grew 2%. Operating income advanced 5.3% to $61.8 million, aided by improved pricing and volume but restrained by inflation and lower productivity. Gross profit increased to $684.2 million from $628 million in the prior-year quarter. Gross margin expanded 69 basis points (bps) year over year to 45.8%, despite a 6% increase in cost of revenues. Selling, general and administrative expenses increased 4.5% to $369.7 million, while research and development expenses rose 8.3% to $28.6 million. Total operating expenses increased 4.3% to $398.3 million. Adjusted income from operations advanced 12% to $354.8 million and the adjusted operating margin expanded 99 bps to 23.8%. Cash and cash equivalents increased to $482.3 million as of June 30, 2026, from $439.6 million as of March 31, 2026. Long-term indebtedness declined to $1.65 billion from $1.81 billion. STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote Cumulative cash flow from operating activities totaled $367.1 million compared with $420 million a year ago. The company also repurchased $115.5 million of ordinary shares and paid $61.4 million in dividends during the quarter. STERIS reiterated fiscal 2027 as-reported revenue growth guidance of 7-8%. Constant-currency organic revenue growth is still expected in the range of 6-7%. The Zacks Consensus Estimate is pegged at $6.37 billion, implying 7.4% growth from fiscal 2025. Adjusted earnings per share are projected to be between $11.10 and $11.30.  The Zacks Consensus Estimate for the metric is pegged at $11.17. STERIS ended first-quarter fiscal 2027 with mixed results, with earnings beating estimates but revenues missing the same. However, the expansion of both the margins looks encouraging. The quarter reflected stable demand across its Healthcare segment. Share gains in consumables and services have fueled the performance, underpinned by solid order growth for capital equipment. Meanwhile, management flagged tariffs and inflation as notable offsets. STE currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Quest Diagnostics DGX and Medpace MEDP. Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%. Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%. DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%. Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%. MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59 Targeted restructuring plan announced associated with new Formulated Chemistries Center of Excellence in North Carolina DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter. “We are pleased with our performance in the first quarter,” said Dan Carestio, President and CEO of STERIS. “Our first quarter results reflected stable underlying demand, while our commercial teams continue to drive meaningful growth within the Healthcare segment. In particular, share gains in consumables and services are fueling our performance, underpinned by solid order growth for capital equipment. Our revenue and earnings expectations for the year are unchanged, as the strength of our portfolio continues to enable us to help our Customers navigate a complex operating environment.” Total Company First Quarter ResultsAs reported, net income for the first quarter was $200.1 million, or $2.04 per diluted share, compared with net income of $177.4 million, or $1.79 per diluted share, in the first quarter of fiscal 2026. Adjusted net income for the first quarter of fiscal 2027 was $253.4 million, or $2.59 per diluted share, compared with the previous year’s first quarter of $231.2 million or $2.34 per diluted share. First Quarter Segment Results Healthcare revenue as reported grew 8% in the first quarter to $1.05 billion compared with $974.7 million in the first quarter of fiscal 2026. This performance reflected 10% improvement in service revenue, 9% growth in consumable revenue, and a 1% increase in capital equipment revenue. Constant currency organic revenue growth was 6%. Healthcare operating income was $260.2 million compared with $235.5 million in last year’s first quarter. The increase in operating income was primarily due to improved volume, price, productivity and favorable mix, which were somewhat offset by inflation and increased tariff costs. Fiscal 2027 first quarter revenue for Applied Sterilization Technologies (AST) increased 6% as reported to $297.6 million compared with $281.2 million in the same period last year. This performance reflected 6% growth in service revenue and a 13% decline in capital equipment revenue. Constant currency organic revenue growth was 5%. Segment operating income was $142.9 million in the first quarter of fiscal 2027, compared with operating income of $136.7 million in the same period last year. The increase in operating income compared with the prior year primarily reflects improved price, which was partially offset by increased depreciation and labor. Life Sciences first quarter revenue as reported increased 9% to $146.7 million compared with $135.2 million in the first quarter of fiscal 2026. This performance reflected 17% growth in capital equipment revenue, 8% improvement in consumable revenue, and 2% growth in service revenue. Constant currency organic revenue increased 8%. Operating income increased to $61.8 million in the first quarter of fiscal 2027 compared with $58.7 million in the prior year’s first quarter. The increase in operating income reflects improvement in price and volume, somewhat offset by inflation and lower productivity. Cash Flow Net cash provided by operations for the first quarter of fiscal 2027 was $367.1 million, compared with $420.0 million in the first quarter of fiscal 2026. Free cash flow for the first quarter of fiscal 2027 was $279.6 million compared with $326.5 million in the prior year period. The decrease in cash flow from operations and free cash flow was driven primarily by a significantly lower contribution from working capital in fiscal 2027 compared with fiscal 2026, partially offset by higher net income. RestructuringSTERIS today is also announcing a targeted restructuring plan in connection with its recent announcement to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina. The investment is expected to accelerate innovation, expand capacity and optimize our U.S. chemistries manufacturing and distribution network. Once complete, the plan includes the anticipated closure of chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota. The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, consisting of approximately $40 million to $50 million of cash expenditures and approximately $15 million to $20 million of non-cash charges. Cash expenditures are expected to primarily consist of Associate retention, severance and benefits, and also include transition, facility exit and other related costs. Non-cash charges are expected to primarily relate to accelerated depreciation. These charges are expected to be incurred over time, with completion anticipated to occur during fiscal 2030, and will be excluded from adjusted earnings measurements. The estimated costs and timing associated with the restructuring actions are based on the Company's current expectations and are subject to various assumptions. Actual results may differ materially from these estimates. Accordingly, the Company may revise its estimates in future periods as implementation activities progress.Fiscal 2027 OutlookThe Company is reiterating its prior guidance for revenue and earnings for fiscal 2027. This includes as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are anticipated to be in the range of $11.10 to $11.30, unchanged from prior expectations. Reflecting the recently announced investment to build a formulated chemistries manufacturing Center of Excellence in North Carolina, capital expenditures are now anticipated to be approximately $450 million compared with prior expectations of $375 million. Free cash flow is now expected to be approximately $800 million compared with prior expectations of $850 million, as the increase in capital expenditures are anticipated to be somewhat offset by the stronger than expected first quarter cash flow. Conference Call As previously announced, STERIS management will host a conference call tomorrow, August 6, 2026, at 9:00 a.m. ET. The conference call can be heard at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the STERIS plc conference call. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET tomorrow either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 9090649 and dial 1-855-669-9658 in the United States or 1-412-317-0088 internationally. About STERIS STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit www.steris.com. Company Contact: Julie Winter, Vice President, Investor Relations and Corporate [email protected] Non-GAAP Financial MeasuresAdjusted net income, adjusted income from operations, free cash flow, adjusted EPS and constant currency organic revenue are non-GAAP measures that may be used from time to time and should not be considered replacements for U.S. GAAP results. Non-GAAP financial measures are presented in this release with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. The Company believes that the presentation of these non-GAAP financial measures, when considered along with our U.S. GAAP financial measures, provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. Adjusted net income, adjusted gross profit, adjusted EPS and adjusted income from operations exclude the amortization of intangible assets acquired in business combinations, acquisition and divestiture related transaction costs and gains or losses, integration costs related to acquisitions, tax restructuring costs, restructuring charges (credits), and certain other unusual or non-recurring items. STERIS believes these measures are useful because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. The Company defines free cash flow as cash flows from operating activities less purchases of property, plant, equipment and intangibles, plus proceeds from the sale of property, plant, equipment, and intangibles. STERIS believes that free cash flow is a useful measure of the Company’s ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares. To measure the percentage organic revenue growth, the Company removes the impact of significant acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales, gross profit, operating income, net earnings and net earnings per diluted share, the most directly comparable U.S. GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with U.S. GAAP results and the reconciliations to corresponding U.S. GAAP financial measures below, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATIONThis release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (b) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with Associates, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (c) the potential of international unrest, military conflicts, economic downturns, currency fluctuations and cybersecurity events and any resulting effects on STERIS’s anticipated growth, performance or other results; (d) changes in healthcare policy or government or other third-party payor reimbursement levels; (e) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the EO litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (f) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a U.S. resident for U.S. federal tax purposes, or the impact of tariffs and/or other trade barriers as a result of STERIS’s corporate structure; (g) the impacts of increasing consolidation and competition within our industry, which may exert pressure on our pricing strategy, manufacturing strategy or lead to decreasing demand for our products and services; (h) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions or from our inability to recruit or retain management and other personnel; (i) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (j) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (k) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated due to unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of acquired businesses; and (l) the possibility that expectations about the benefits, charges and cash expenditures from the new Center of Excellence in North Carolina and the related facility consolidation plan may not be accurate or realized on anticipated timelines, or at all. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Attachment STERIS Q127 Financial Tables

Steris (STE) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.97%. A quarter ago, it was expected that this medical products maker would post earnings of $2.86 per share when it actually produced earnings of $2.83, delivering a surprise of -1.05%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Steris, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.49 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.83%. This compares to year-ago revenues of $1.39 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Steris shares have lost about 8.2% since the beginning of the year versus the S&P 500's gain of 13%. While Steris has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Steris was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.68 on $1.56 billion in revenues for the coming quarter and $11.17 on $6.37 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Artivion (AORT), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6. This biological medical device maker is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of -45.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Artivion's revenues are expected to be $120.9 million, up 7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report Artivion, Inc. (AORT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Steris (STE) reported $1.49 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 7.3%. EPS of $2.59 for the same period compares to $2.34 a year ago. The reported revenue represents a surprise of -0.83% over the Zacks Consensus Estimate of $1.51 billion. With the consensus EPS estimate being $2.54, the EPS surprise was +1.97%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Applied Sterilization Technologies (AST): $297.6 million compared to the $298.63 million average estimate based on two analysts. The reported number represents a change of +5.8% year over year. Revenues- Healthcare Products- Consumables: $391.9 million versus $391.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change. Revenues- Life Sciences: $146.7 million versus $146.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change. Revenues- Healthcare Products- Service: $425.9 million versus $423.71 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change. Revenues- Healthcare: $1.05 billion versus $1.06 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change. Revenues- Healthcare Products- Capital Equipment: $230.5 million versus $243.63 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.4% change. View all Key Company Metrics for Steris here>>> Shares of Steris have returned +8.1% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.33%. A quarter ago, it was expected that this maker of products used in drug discovery and development would post earnings of $2.31 per share when it actually produced earnings of $2.7, delivering a surprise of +16.88%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Waters, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.65 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.25%. This compares to year-ago revenues of $771.33 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Waters shares have lost about 1.3% since the beginning of the year versus the S&P 500's gain of 11%. While Waters has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Waters was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.99 on $1.76 billion in revenues for the coming quarter and $14.51 on $6.44 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Steris (STE), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5. This medical products maker is expected to post quarterly earnings of $2.54 per share in its upcoming report, which represents a year-over-year change of +8.6%. The consensus EPS estimate for the quarter has been revised 1.1% lower over the last 30 days to the current level. Steris' revenues are expected to be $1.51 billion, up 8.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Waters Corporation (WAT) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

STERIS plc STE is scheduled to release first-quarter fiscal 2027 results on Aug. 6, after market close. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.83, which missed the Zacks Consensus Estimate by 1.05%. STE’s earnings beat estimates in two of the trailing four quarters, met once and missed in the other, delivering an average surprise of 0.90%. The Zacks Consensus Estimate for revenues is pegged at $1.51 billion, implying an increase of 8.2% from the year-ago reported figure. The consensus mark for EPS is pegged at $2.54, indicating a year-over-year increase of 8.6%. Estimates for earnings have remained constant at $2.54 per share in the past 30 days. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Healthcare In the previous quarter, growth across all categories was robust. We expect this trend to have continued in the fiscal first quarter as well. The company maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fiscal first-quarter results. Also, capital equipment growth is expected to have remained robust. STERIS completed two tuck-in acquisitions to strengthen its Healthcare portfolio and expand its global reach. The company vertically integrated its MEDglas wall supplier, extending this business into international markets. It acquired a family of gastrointestinal (GI) products, broadening its product portfolio and enhancing its distribution channels. Management expects these two acquisitions to contribute a combined $45 million in revenues during fiscal 2027. The Zacks Consensus Estimate for the segment’s revenues implies an improvement of 9% from the year-ago reported figure. Applied Sterilization Technologies (“AST”) In the fiscal first quarter, Steris is expected to have experienced organic revenue growth within this segment. With over $1 billion in revenues in fiscal 2026, AST crossed a new milestone, exceeding $500 million in operating profit. We expect this momentum to have persisted in the to-be-reported quarter as well. The Zacks Consensus Estimate for the segment’s revenues calls for an increase of 5.6% year over year. STERIS plc price-eps-surprise | STERIS plc Quote Life Sciences The segment's fiscal fourth-quarter 2025 revenues rose year over year due to strong growth in consumables revenues. The segment also experienced a capital equipment increase as customers returned to capital investment. These trends might have continued in the to-be-reported quarter. The Zacks Consensus Estimate for the segment’s revenues suggests an increase of 7.6% year over year. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here. Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company currently has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around: Hinge Health Inc. HNGE has an Earnings ESP of +4.24% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon. In the trailing four quarters, HINGE delivered an average earnings surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago reported figure. Neurocrine Biosciences NBIX has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon. NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure. West Pharmaceutical Services WST has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23. WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE) : Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Hinge Health Inc. (HNGE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 5, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 6, 2026, either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 9090649 and dial 1-855-669-9658 in the United States or 1-412-317-0088 internationally. About STERIS STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.   For more information, visit www.steris.com. Company Contact: Julie Winter, Vice President, Investor Relations and Corporate Communications [email protected] 440.392.7245 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATIONThis release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.